Saroglitazar

Catalog No.S9674 Batch:S967401

Technical Data

Formula	C₂₅H₂₉NO₄S
Molecular Weight	439.57	CAS No.	495399-09-2
Solubility (25°C)*	In vitro


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Biological Activity

Description

Saroglitazar (Lipaglyn, ZYH1) is an agonist of peroxisome proliferator-activated receptor (PPAR) with EC50 of 0.65 pM and 3 nM for hPPARα and hPPARγ in HepG2 cells, respectively.

Targets

hPPARα ^[1] (Cell-free assay)	hPPARγ ^[1] (Cell-free assay)
0.65 pM(EC50)	3 nM(EC50)

In vitro

Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and glucose metabolism by activating peroxisome proliferator-activated receptors (PPAR). The EC50 values of Saroglitazar assessed in HepG2 cells using PPAR transactivation assay for hPPARa and hPPARc are 0.65 pmol/L and 3 nmol/L, respectively.^[1]

In vivo

In db/db mice, 12-day treatment with Saroglitazar (0.01–3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. Significant reduction in serum TG (upto 90%) is also observed in Zucker fa/fa rats, Swiss albino mice, and in high fat -high cholesterol (HF-HC)-fed Golden Syrian hamsters. LDL cholesterol is significantly lowered in hApoB100/hCETP double transgenic mice and HF-HC diet fed Golden Syrian Hamsters. Hyperinsulinemic-Euglycemic clamp study in Zucker fa/fa rats demonstrates potent insulin-sensitizing activity. Saroglitazar also shows a significant decrease in SBP (22 mmHg) and increase (62.1%) in serum adiponectin levels in Zucker fa/fa rats. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans.^[1]

Density

1.15 g/mL

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines HepG2 cells Concentrations -- Incubation Time 20-22 h Method HepG2 cells are seeded in 12-well plates at a density of 400,000 cells/well in 1 mL of medium per well. Cells are transfected with PPRE3-TK-luc and 0.08 μg of the pCDNA expression vector containing the cDNA of PPARa or 0.08 μg of the pSG5 expression vector containing the cDNA of PPARc using Superfect. Cells are incubated at 37 ℃, 5% CO2: 95% O2 and after 3 h 1.0 mL of the medium containing Saroglitazar are added to the respective wells. After the incubation for 20–22 h at 37 ℃ under 5% CO2, cells are first washed with Phosphate Buffer Saline (pH 7.3- 7.4), lysed and supernatant collected for luciferase and bgalactosidase activity. The luciferase activity is determined using commercial firefly luciferase assay according to the suppliers’ instructions in white 96-well plate. The bgalactosidase activity is determined in ELISA reader at 415 nm.
Animal Study:^{^[1]}	Animal Models B6.BKS(D)-Lepr^db/J(db/db) mice Dosages 0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg Administration Oral gavage

Cell Assay:^{^[1]}

Cell lines
HepG2 cells
Concentrations
--
Incubation Time
20-22 h
Method
HepG2 cells are seeded in 12-well plates at a density of 400,000 cells/well in 1 mL of medium per well. Cells are transfected with PPRE3-TK-luc and 0.08 μg of the pCDNA expression vector containing the cDNA of PPARa or 0.08 μg of the pSG5 expression vector containing the cDNA of PPARc using Superfect. Cells are incubated at 37 ℃, 5% CO2: 95% O2 and after 3 h 1.0 mL of the medium containing Saroglitazar are added to the respective wells. After the incubation for 20–22 h at 37 ℃ under 5% CO2, cells are first washed with Phosphate Buffer Saline (pH 7.3- 7.4), lysed and supernatant collected for luciferase and bgalactosidase activity. The luciferase activity is determined using commercial firefly luciferase assay according to the suppliers’ instructions in white 96-well plate. The bgalactosidase activity is determined in ELISA reader at 415 nm.

Animal Study:^{^[1]}

Animal Models
B6.BKS(D)-Lepr^db/J(db/db) mice
Dosages
0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg
Administration
Oral gavage

References

[1] Mukul R Jain, et al. Pharmacol Res Perspect. 2015 Jun;3(3):e00136.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.